Receptor tyrosine kinase gene expression profiling of orbital rhabdomyosarcoma unveils MET as a potential biomarker and therapeutic target
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Receptor tyrosine kinase gene expression profiling of orbital rhabdomyosarcoma unveils MET as a potential biomarker and therapeutic target
Authors
Keywords
-
Journal
Human Cell
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-11-02
DOI
10.1007/s13577-023-00993-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Neratinib: the emergence of a new player in the management of HER2+ breast cancer brain metastasis
- (2020) Azadeh Nasrazadani et al. Future Oncology
- Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
- (2020) Alexander Drilon et al. NATURE MEDICINE
- Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients.
- (2020) Xiuning Le et al. JOURNAL OF CLINICAL ONCOLOGY
- Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC).
- (2020) Justin F. Gainor et al. JOURNAL OF CLINICAL ONCOLOGY
- Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.
- (2020) Qiu Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.
- (2020) Vivek Subbiah et al. JOURNAL OF CLINICAL ONCOLOGY
- Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
- (2020) Paul K. Paik et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Prospective Study of Apatinib in Patients with Extensive‐Stage Small Cell Lung Cancer After Failure of Two or More Lines of Chemotherapy
- (2020) Yutao Liu et al. ONCOLOGIST
- Neratinib and capecitabine for breast cancer brain metastases
- (2019) Robert Stirrups LANCET ONCOLOGY
- MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
- (2019) Qiming Wang et al. Journal of Hematology & Oncology
- Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)
- (2019) Jang Ho Cho et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanisms of receptor tyrosine kinase activation in cancer
- (2018) Zhenfang Du et al. Molecular Cancer
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations
- (2018) Sumanta K. Pal et al. Cancer Discovery
- Advances and Challenges on Management of Gastrointestinal Stromal Tumors
- (2018) Lin Mei et al. Frontiers in Oncology
- Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer
- (2018) Baohui Han et al. JAMA Oncology
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- High VEGFR1/2 expression levels are predictors of poor survival in patients with cervical cancer
- (2017) Yun-Zhi Dang et al. MEDICINE
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patients
- (2016) Paola Griseri et al. Oncotarget
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- The receptor tyrosine kinase Axl in cancer: Biological functions and therapeutic implications
- (2013) Juliano D. Paccez et al. INTERNATIONAL JOURNAL OF CANCER
- Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
- (2013) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- The Relationship between Over-expression of Glial Cell-derived Neurotrophic Factor and Its RET Receptor with Progression and Prognosis of Human Pancreatic Cancer
- (2013) Q Zeng et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- Contrasted Outcomes to Gefitinib on Tumoral IGF1R Expression in Head and Neck Cancer Patients Receiving Postoperative Chemoradiation (GORTEC Trial 2004-02)
- (2012) J. Thariat et al. CLINICAL CANCER RESEARCH
- Radiotherapy for Rhabdomyosarcoma: Indications and Outcome
- (2012) S.A. Terezakis et al. CLINICAL ONCOLOGY
- FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features
- (2012) Sara A. Byron et al. PLoS One
- Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274
- (2011) Jinxuan Hou et al. Journal of Translational Medicine
- Differential Mechanisms of Acquired Resistance to Insulin-like Growth Factor-I Receptor Antibody Therapy or to a Small-Molecule Inhibitor, BMS-754807, in a Human Rhabdomyosarcoma Model
- (2010) F. Huang et al. CANCER RESEARCH
- Reactive oxygen species in cancer
- (2010) Geou-Yarh Liou et al. FREE RADICAL RESEARCH
- PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas
- (2010) T. Ozawa et al. GENES & DEVELOPMENT
- Insulin-like growth factors I and II receptors in the breast cancer survival disparity among African–American women
- (2010) S. Kalla Singh et al. GROWTH HORMONE & IGF RESEARCH
- Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
- (2010) J. Weiss et al. Science Translational Medicine
- Tumour formation by single fibroblast growth factor receptor 3-positive rhabdomyosarcoma-initiating cells
- (2009) M Hirotsu et al. BRITISH JOURNAL OF CANCER
- The Insulin-like Growth Factor-1 Receptor-Targeting Antibody, CP-751,871, Suppresses Tumor-Derived VEGF and Synergizes with Rapamycin in Models of Childhood Sarcoma
- (2009) R. T. Kurmasheva et al. CANCER RESEARCH
- PDGFRα: a new therapeutic target in the treatment of hepatocellular carcinoma?
- (2009) Abdul M Oseini et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Immunohistochemical detection of EGFR, fibrillin-2, P-cadherin and AP2β as biomarkers for rhabdomyosarcoma diagnostics
- (2009) Beate Grass et al. HISTOPATHOLOGY
- Phase II Multicenter Trial of Imatinib in 10 Histologic Subtypes of Sarcoma Using a Bayesian Hierarchical Statistical Model
- (2009) Rashmi Chugh et al. JOURNAL OF CLINICAL ONCOLOGY
- Extraconal orbital tumors in children—a spectrum
- (2009) Seethalakshmi Viswanathan et al. VIRCHOWS ARCHIV
- Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
- (2008) Antonis C. Antoniou et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Clinical Significance of CXC Chemokine Receptor-4 and c-Met in Childhood Rhabdomyosarcoma
- (2008) F. Diomedi-Camassei et al. CLINICAL CANCER RESEARCH
- Recent Advances in the Development of Multi-Kinase Inhibitors
- (2008) Martin Krug et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma
- (2008) E Taniguchi et al. ONCOGENE
- Expression of Insulin-Like Growth Factor Pathway Proteins in Rhabdomyosarcoma: IGF-2 Expression is Associated with Translocation-Negative Tumors
- (2008) Shalini Makawita et al. PEDIATRIC AND DEVELOPMENTAL PATHOLOGY
- Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program
- (2007) John M. Maris et al. PEDIATRIC BLOOD & CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More